{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:26:36Z","timestamp":1790670396468,"version":"4.1.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Preclinical and clinical studies suggest that the multimodal antidepressant vortioxetine may offer a valuable therapeutic option in the treatment of depression associated with neurological disorders, including Parkinson\u2019s disease (PD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the effect of vortioxetine and the SSRI sertraline in the treatment of PD and comorbid depression, placing emphasis on peripheral inflammation markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is an observational longitudinal study. We have recruited 33 patients affected by PD with comorbid depression, evaluated for motor and non-motor symptoms, depression, and peripheral and soluble markers of inflammation at baseline and at the end of antidepressant treatment. Patients were divided into two groups treated with either vortioxetine (10\u201320\u202fmg\/day) or sertraline (50\u202fmg\/day) for 4\u202fmonths. A group of 12 healthy controls was also used for comparative purposes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline PD patients showed a higher number of \u201cclassical\u201d monocytes and a lower number of \u201cnon-classical\u201d monocytes and myeloid dendritic cells (mDCs). The number and activity of DCs generated from isolated monocytes were also lower in PD patients. While both sertraline and vortioxetine treatment further reduced the number of mDCs, only vortioxetine had a restorative effect on CD40- and CD54-expressing DCs and their function. Both drugs display an antidepressant activity, but vortioxetine was superior to sertraline in improving cognitive function, anxiety, anhedonia, and apathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These data evaluate for the first time the immunomodulatory effects of two different treatments in PD patients with comorbid depression, highlighting the greater immunomodulatory capacity of vortioxetine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnins.2026.1761550","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:33:08Z","timestamp":1769092388000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative effect of vortioxetine and sertraline on clinical and inflammatory profile in Parkinson\u2019s disease with comorbid depression"],"prefix":"10.3389","volume":"20","author":[{"given":"Marika","family":"Alborghetti","sequence":"first","affiliation":[{"name":"Department of Neurosciences, Mental Health, and Sensory Organs, Sapienza University of Rome","place":["Rome, Italy"]},{"name":"IRCCS Neuromed","place":["Pozzilli, Italy"]},{"name":"Center for Parkinson\u2019s Disease, IRCCS San Raffaele Pisana","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Moliterni","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Bianchini","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Mental Health, and Sensory Organs, Sapienza University of Rome","place":["Rome, Italy"]},{"name":"AGEIS, Universit\u00e9 Grenoble Alpes","place":["Grenoble, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domiziana","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Mental Health, and Sensory Organs, Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Caissutti","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Capozzi","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana Giada","family":"Radicati","sequence":"additional","affiliation":[{"name":"Center for Parkinson\u2019s Disease, IRCCS San Raffaele Pisana","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Moschillo","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Mental Health, and Sensory Organs, Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Marino","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Mental Health, and Sensory Organs, Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Berardelli","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Mental Health, and Sensory Organs, Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Salvetti","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Mental Health, and Sensory Organs, Sapienza University of Rome","place":["Rome, Italy"]},{"name":"IRCCS Neuromed","place":["Pozzilli, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Nicoletti","sequence":"additional","affiliation":[{"name":"IRCCS Neuromed","place":["Pozzilli, Italy"]},{"name":"Department of Physiology and Pharmacology, Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Misasi","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Ernesto","family":"Pontieri","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Mental Health, and Sensory Organs, Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jad.2023.01.074","article-title":"Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: an updated analysis of efficacy and tolerability","volume":"328","author":"Adair","year":"2023","journal-title":"J. Affect. Disord."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12974-019-1606-1","article-title":"Regulatory impairment in untreated Parkinson\u2019s disease is not restricted to Tregs: other regulatory populations are also involved","volume":"16","author":"\u00c1lvarez-Luqu\u00edn","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"ref3","volume-title":"Diagnostic and statistical manual of mental disorders, 5th edition (DSM-5)","year":"2013"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1076\/1380-3395(200008)22:4;1-0;FT518","article-title":"Trail making test, part B as a measure of executive control: validation using a set-switching paradigm","volume":"22","author":"Arbuthnott","year":"2000","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jad.2016.07.015","article-title":"A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms","volume":"206","author":"Baldwin","year":"2016","journal-title":"J. Affect. Disord."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/ijnp\/pyx070","article-title":"A network meta-analysis comparing effects of various antidepressant classes on the digit symbol substitution test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder","volume":"21","author":"Baune","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e1208","DOI":"10.1038\/tp.2017.155","article-title":"Repeated exposure to systemic inflammation and risk of new depressive symptoms among older adults","volume":"7","author":"Bell","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40262-017-0612-7","article-title":"Vortioxetine: clinical pharmacokinetics and drug interactions","volume":"57","author":"Chen","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e65352","DOI":"10.1371\/journal.pone.0065352","article-title":"Blood dendritic cell frequency declines in idiopathic Parkinson\u2019s disease and is associated with motor symptom severity","volume":"8","author":"Ciaramella","year":"2013","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"104749","DOI":"10.1016\/j.neubiorev.2022.104749","article-title":"Prevalence and clinical aspects of depression in Parkinson\u2019s disease: a systematic review and meta-analysis of 129 studies","volume":"141","author":"Cong","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41573-021-00368-1","article-title":"Immune targets for therapeutic development in depression: towards precision medicine","volume":"21","author":"Drevets","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41577-018-0088-1","article-title":"Dendritic cell subsets in T cell programming: location dictates function","volume":"19","author":"Eisenbarth","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3390\/biomedicines13040915","article-title":"A novel frontier in gut-brain axis research: the transplantation of fecal microbiota in neurodegenerative disorders","volume":"13","author":"Eslami","year":"","journal-title":"Biomedicine"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3390\/ph18020197","article-title":"The anti-inflammatory potential of tricyclic antidepressants (TCAs): a novel therapeutic approach to atherosclerosis pathophysiology","volume":"18","author":"Eslami","year":"","journal-title":"Pharmaceuticals"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1017\/neu.2023.58","article-title":"About the paper \u2018Apathy associated with antidepressants: a systematic review\u2019","volume":"36","author":"Fagiolini","year":"2024","journal-title":"Acta Neuropsychiatr."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jad.2020.11.106","article-title":"Effectiveness of vortioxetine on emotional blunting in patients with major depressive disorder with inadequate response to SSRI\/SNRI treatment","volume":"283","author":"Fagiolini","year":"2021","journal-title":"J. Affect. Disord."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00401-014-1345-4","article-title":"Inflammatory dysregulation of blood monocytes in Parkinson\u2019s disease patients","volume":"128","author":"Grozdanov","year":"2014","journal-title":"Acta Neuropathol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/mds.870120522","article-title":"Sertraline for the treatment of depression in Parkinson\u2019s disease","volume":"12","author":"Hauser","year":"1997","journal-title":"Mov. Disord."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1016\/S0924-977X(16)31265-2","article-title":"The digit symbol substitution test (DSST): psychometric properties and clinical utility in major depressive disorder","volume":"26","author":"Jaeger","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1358\/dot.2019.55.7.2958474","article-title":"Gepirone hydrochloride: a novel antidepressant with 5-HT1A agonistic properties","volume":"55","author":"Kaur Gill","year":"2019","journal-title":"Drugs Today"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/jamapsychiatry.2014.1332","article-title":"Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study","volume":"71","author":"Khandaker","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/07067437241245384","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults: R\u00e9seau canadien pour les traitements de l\u2019humeur et de l\u2019anxi\u00e9t\u00e9 (CANMAT) 2023: Mise \u00e0 jour des lignes directrices cliniques pour la prise en charge du trouble d\u00e9pressif majeur chez les adultes","volume":"69","author":"Lam","year":"2024","journal-title":"Can. J. Psychiatr."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.biopsych.2018.12.020","article-title":"Longitudinal association between depression and inflammatory markers: results from the Netherlands study of depression and anxiety","volume":"85","author":"Lamers","year":"2019","journal-title":"Biol. Psychiatry"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/mds.22229","article-title":"Apathy and anhedonia rating scales in Parkinson\u2019s disease: critique and recommendations","volume":"23","author":"Leentjens","year":"2008","journal-title":"Mov. Disord."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/mds.23184","article-title":"Anxiety rating scales in Parkinson\u2019s disease: a validation study of the Hamilton anxiety rating scale, the Beck anxiety inventory, and the hospital anxiety and depression scale","volume":"26","author":"Leentjens","year":"2011","journal-title":"Mov. Disord."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1136\/jnnp.51.11.1401","article-title":"Parkinson\u2019s disease and depression: psychometric properties of the Beck depression inventory","volume":"51","author":"Levin","year":"1988","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e47387","DOI":"10.1371\/journal.pone.0047387","article-title":"Non-motor symptoms in patients with Parkinson\u2019s disease\u2014correlations with inflammatory cytokines in serum","volume":"7","author":"Lindqvist","year":"2012","journal-title":"PLoS One"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/02698811211069110","article-title":"Modulation of microglial activation by antidepressants","volume":"36","author":"Mariani","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10072-018-3260-2","article-title":"Assessment of Snaith-Hamilton Pleasure Scale (SHAPS): the dimension of anhedonia in Italian healthy sample","volume":"39","author":"Martino","year":"2018","journal-title":"Neurol. Sci."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"eabi4613","DOI":"10.1126\/sciimmunol.abi4613","article-title":"Transforming growth factor-\u03b21 in regulatory T cell biology","volume":"7","author":"Moreau","year":"2022","journal-title":"Sci. Immunol."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12991-025-00609-2","article-title":"Pro-inflammatory cytokines level in depressed patients with suicidal behaviour: a systematic review and meta-analysis","volume":"24","author":"Moshfeghinia","year":"2025","journal-title":"Ann. General Psychiatry"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3390\/biomedicines13030589","article-title":"Cytokine signaling in diabetic neuropathy: a key player in peripheral nerve damage","volume":"13","author":"Nashtahosseini","year":"2025","journal-title":"Biomedicine"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1001\/jamaneurol.2016.2742","article-title":"Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis","volume":"73","author":"Qin","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/2013.jamapsychiatry.4","article-title":"A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers","volume":"70","author":"Raison","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/mds.21803","article-title":"A systematic review of prevalence studies of depression in Parkinson\u2019s disease","volume":"23","author":"Reijnders","year":"2008","journal-title":"Mov. Disord."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","article-title":"Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data","volume":"145","author":"Sanchez","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.3390\/brainsci12111466","article-title":"Vortioxetine improves depressive symptoms and cognition in Parkinson\u2019s disease patients with major depression: an open-label prospective study","volume":"12","author":"Santos Garc\u00eda","year":"2022","journal-title":"Brain Sci."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3389\/fpsyg.2017.00557","article-title":"The Stroop color and word test","volume":"8","author":"Scarpina","year":"2017","journal-title":"Front. Psychol."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/08919887241254471","article-title":"Greater apathy associated with selective serotonin reuptake inhibitor use in Parkinson\u2019s disease","volume":"38","author":"Schade","year":"2025","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.pharep.2017.01.030","article-title":"Vortioxetine: a review of the pharmacology and clinical profile of the novel antidepressant","volume":"69","author":"Sowa-Ku\u0107ma","year":"2017","journal-title":"Pharmacol. Rep."},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.2174\/011570159X361647250416072053","article-title":"Vortioxetine for the treatment of depression in patients with Parkinson\u2019s disease: a 16-week pilot, prospective, open-label safety study","author":"Stocchi","year":"2025","journal-title":"Curr. Neuropharmacol."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"115760","DOI":"10.1016\/j.bmc.2020.115760","article-title":"Design, synthesis and biological evaluation of vortioxetine derivatives as new COX-1\/2 inhibitors in human monocytes","volume":"28","author":"Talmon","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/bph.14074","article-title":"Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes\/macrophages","volume":"175","author":"Talmon","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","article-title":"Inflammation and immune dysfunction in Parkinson disease","volume":"22","author":"Tansey","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"e13268","DOI":"10.1111\/eci.13268","article-title":"The impact of tocilizumab on anxiety and depression in patients with rheumatoid arthritis","volume":"50","author":"Tiosano","year":"2020","journal-title":"Eur. J. Clin. Investig."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/JCP.0000000000001153","article-title":"Efficacy and adverse effects of tranylcypromine and tricyclic antidepressants in the treatment of depression: a systematic review and comprehensive meta-analysis","volume":"40","author":"Ulrich","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1177\/07067437241303031","article-title":"Canadian network for mood and anxiety treatments 2024 clinical practice guideline for the management of perinatal mood, anxiety, and related disorders: guide de pratique 2024 du Canadian Network for Mood and Anxiety Treatments pour le traitement des troubles de l\u2019humeur, des troubles anxieux et des troubles connexes p\u00e9rinatals","volume":"70","author":"Vigod","year":"2025","journal-title":"Can. J. Psychiatr."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1038\/tp.2012.8","article-title":"Association of depressive disorders, depression characteristics and antidepressant medication with inflammation","volume":"2","author":"Vogelzangs","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/01.JGP.0000192488.66049.4b","article-title":"Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease","volume":"14","author":"Weintraub","year":"2006","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.bbi.2020.01.018","article-title":"Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson\u2019s disease","volume":"87","author":"Wijeyekoon","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/mds.26563","article-title":"Serum immune markers and disease progression in an incident Parkinson\u2019s disease cohort (ICICLE-PD)","volume":"31","author":"Williams-Gray","year":"2016","journal-title":"Mov. Disord."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"6S","DOI":"10.1097\/00004714-199006001-00003","article-title":"Neurochemistry and neurophysiology of buspirone and gepirone: interactions at presynaptic and postsynaptic 5-HT1A receptors","volume":"10","author":"Yocca","year":"1990","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"e15750","DOI":"10.7759\/cureus.15750","article-title":"Vortioxetine improved depressive state in Parkinson\u2019s disease","volume":"13","author":"Yoshimura","year":"2021","journal-title":"Cureus"}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2026.1761550\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:33:09Z","timestamp":1769092389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2026.1761550\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":54,"alternative-id":["10.3389\/fnins.2026.1761550"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2026.1761550","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"article-number":"1761550"}}